It has been repetitively confirmed that these BCR-ABL+ LSK cells are exclusively capable of inducing CML in secondary recipients in a dose dependent manner [46, 47]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.